What is UBS's price target for PACB?

UBS's latest stated price target for Pacific Biosciences of California Inc. (PACB) is $1.35, from its action on Sep 9, 2026.

What is UBS's rating on PACB?

UBS rates PACB Neutral, a neutral rating, as of Sep 9, 2026.

When did UBS last change its view on PACB?

On Sep 9, 2026, UBS resumes coverage at Neutral, price target $1.35.

Analyst firms · UBS · PACB

UBS PACB price target and rating history

Pacific Biosciences of California Inc. (PACB) · Industrials

UBS rates Pacific Biosciences of California Inc. (PACB) Neutral with a $1.35 price target, as of its latest action on Sep 9, 2026. It has published 4 rating actions on PACB since February 2023, including 1 upgrade and 1 downgrade.

Current rating: Neutral
Price target: $1.35
Median target, all firms: Too few
Actions on PACB: 4

UBS price target on PACB

UBS price target on PACB, each point a stated target, February 2023 to September 2026.

Every UBS rating on PACB

Sep 9, 2026
ResumeUBS resumes coverage at Neutral, price target $1.35
Nov 11, 2024
DowngradeUBS downgrades to Neutral from Buy
Nov 17, 2023
UpgradeUBS upgrades to Buy from Neutral, price target $13 to $10
Feb 2, 2023
InitiateUBS starts coverage at Neutral, price target $13

How other firms rate PACB

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
UBS	Neutral	$1.35	Sep 9, 2026
Barclays	Underweight	$1.50	Mar 6, 2026

Questions about UBS and PACB

What is UBS's price target for PACB?: UBS's latest stated price target for Pacific Biosciences of California Inc. (PACB) is $1.35, from its action on Sep 9, 2026.
What is UBS's rating on PACB?: UBS rates PACB Neutral, a neutral rating, as of Sep 9, 2026.
When did UBS last change its view on PACB?: On Sep 9, 2026, UBS resumes coverage at Neutral, price target $1.35.

More PACB rating histories

Cantor Fitzgerald3

All UBS ratings PACB news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.